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Abstract: The aim of the study was to critically assess and review the latest evidence relating the
associations between host defence peptides (HDPs), periodontal diseases (PD) and diabetes mellitus
type 2 (DM2). To explore studies on HDPs, periodontal disease, and DM2, researchers utilised
specific key phrases to search the electronic databases PubMed (National Library of Medicine),
Embase (Ovid), Medline (EBSCO), and Dentistry and Oral Sciences (EBSCO). Quality assessment was
conducted by means of the Newcastle Ottawa scale and the Systematic Review Centre for Laboratory
Animal Experimentation (SYRCLE) tool. Following a thorough screening process, a total of 12 papers
(4 case-control, 6 cross-sectional, 1 animal, and 1 in vitro) fulfilled the selection criteria and were
included. The majority of research found that HDPs were upregulated in DM2 patients with PD.
Three investigations, however, found that HDPs were downregulated in DM2 patients with PD.
HDPs play a part in the pathophysiology of PD and DM2. Nonetheless, more human, animal and
laboratory investigations are needed to fully understand validation of the link, as the evidence is
limited. Understanding HDPs as common moderators is critical, aimed at unlocking their potential
as therapeutic and diagnostic agents.
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1. Introduction
Dental plaque biofilm is the primary cause of periodontal disease (PD), leading to
progressive deterioration of periodontal apparatus [1]. PDs are caused by a series of
events involving the non-specific defence mechanism (innate) and antigen-specific immune
response (acquired) [2]. Host defence peptides (HDPs) that are largely produced by
epithelial cells and the acute inflammatory cells, i.e., neutrophils, and have antimicrobial
characteristics are a vital constituent of the non-specific defence system. [3,4]. Human
saliva as well as gingival crevicular fluid (GCF) contain plentiful HDPs, comprising human
alpha- (hADs) and beta-defensins (hBDs), cathelicidin (hCAP18/LL-37), adrenomedullin,
histatin, and others [5–8]. These HDPs play a significant role in the maintenance of the
periodontal pocket and help in combating microbes.
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Aside from their well-known antibacterial activity, they also contribute to innate
and adaptive immunity by boosting phagocytosis, decreasing proinflammatory cytokine
production, and modulating the complement system [9]. They operate as immune cell
chemoattractants and promote wound healing and angiogenesis [10]. Despite their welldefined impacts on immunity, it is unclear how periodontitis and associated variables
influence antimicrobial peptide levels [11–14].
Diabetes mellitus type 2 (DM2) is a chronic metabolic condition characterised by
insulin resistance. The disease occurrence is anticipated to be above 400 million people
(20–79 years old) globally, with 629 million expected by 2045 [15]. It is also regarded as a
modifiable periodontitis risk factor [16,17]. The immune-inflammatory axis is disrupted
in both PD and DM2. To untangle their interaction and develop treatment strategies, a
comprehensive knowledge of the fundamental biological processes is required.
HDPs have been identified as important players in immune modulation in this regard [18,19]. Studies have shown that HDPs are involved both in the initiation/progression
of PD and in the immune-inflammatory reactions that characterise PD risk factors such
as DM2 [20,21] and other risk factors such as smoking [22], psychological stress [23], and
human immunodeficiency virus (HIV) [24]. However, it is yet unknown how and if HDPs
have a role in the relationship between PD and DM2. This systematic review was aimed
at giving the recent available information on the HDPs’ involvement in PD and one of its
major risk factors, DM2.
2. Materials and Methods
2.1. Focused Question
“Is there any likely association of HDPs in patients with PD and DM2?”
This systematic review was devised in accordance with the most recent Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) recommendations [25].
2.2. Literature Search
A total of four electronic databases, PubMed (National Library of Medicine, Maryland,
United States of America), Embase (Ovid), Medline (EBSCO), and Dentistry and Oral
Sciences (EBSCO) were used to conduct literature searches from January 1990 to January
2021. The following search method was used to find relevant literature on the association
between HDPs, PD, and DM, using Boolean operators; “Periodontal disease” OR “Chronic
periodontitis” OR “periodontitis” AND “diabetes” OR “diabetes mellitus” OR “diabetes
mellitus type 2” AND “antimicrobial peptide” OR “defensin” OR “cathelicidin”. Further
literature was found by searching the bibliographical lists of pertinent articles. Relevant
papers were found and rigorously analysed in order to interpret the findings. Table S1
represents search tracking of this review paper.
2.3. Screening and Selection Process
The screening process was performed by two different authors (M.S.Z. and M.S.S.).
Screening was conducted in three phases, i.e., titles, abstracts and full texts. The Cohen
Kappa score (κ) [26] was used to assess the authors’ inter-rater agreement. In the event of a
disagreement or discrepancy, a third reviewer was consulted to reach a consensus.
Excluded were in vivo studies on HDPs’ expression in GCF/saliva/gingival tissue
(GT) of DM2 and periodontally healthy individuals. Furthermore, in vivo studies on HDPs’
expression in GCF/saliva/GT of patients with periodontitis but not having DM2 were
excluded. However, studies on HDPs’ expression in GCF/saliva/GT of individuals with
periodontitis suffering from DM2 were included. Laboratory investigations on the effect of
DM on expression of HDP in human oral epithelial/keratinocyte cells were also included.
Figure 1 depicts the search process.

Diagnostics 2021, 11, 2210

3 of 12

Figure 1. Search strategy used to search articles.

2.4. Eligibility Criteria and Data Extraction
The search was restricted to papers written in English. In vivo studies involving
humans or animals of all ages, regardless of gender, were included. Also included were
in vitro research on cultured cells, human gingival keratinocytes or epithelial cells. Languages other than English, review articles, studies presented as abstracts of scientific conferences, and other unpublished papers were all excluded. The data extraction comprised
the name of author, study year, the tissue/fluid analysed in the study, the investigated
HDP, details regarding participants, main results of the study, and the change model.
2.5. Quality Appraisal
The quality appraisal was implemented by means of the Newcastle Ottawa scale
(NOS) for case-control papers [27], NOS modified for cross-sectional research [28], and
the Systematic Review Centre for Laboratory animal Experimentation (SYRCLE) tool for
animal studies [29]. For case-control research, NOS comprises eight items with three
domains, with a maximum score of nine. Because a standard measure for what comprises
a high-quality study has not been generally recognised yet, a score of seven or greater was
rendered to be a high-quality study.

Diagnostics 2021, 11, 2210

4 of 12

For the NOS modified for cross-sectional studies, a score of 9–10 was judged to be a
very good study, a score of 7–8 was classified as a good study, a score of 5–6 was classified
as a satisfactory study, and score of 0–4 was judged to be an unsatisfactory study. In the
case of the SYRCLE tool, six distinct domains were evaluated in a study. A paper was
classified as having low bias risk if each domain had a low bias risk, an unclear bias risk if
any one domain had an unclear bias risk, and a high bias risk if any one domain had a high
bias risk. Two reviewers (M.S.Z. and M.S.S.) independently carried out the data extraction
and quality assessment process.
3. Results
3.1. Search Results
A comprehensive search yielded 223 articles (excluding duplicates). Following the
review of titles, abstracts, and full-texts, 14 papers were available. Furthermore, a manual
search resulted in the inclusion of 15 additional articles. After excluding 17 of the 29 articles,
12 papers were chosen for qualitative analysis (Figure 1). Table 1 displays the study’s
characteristics. The meta-analysis was not possible as a result of heterogeneity of the results
of the papers included. The Cohen’s Kappa score (κ) was found to be 0.81 (titles screening),
0.83 (abstract screening) and 0.92 (full-text screening); that was based on the usually cited
scale for Kappa score interpretation that advocates strong to almost perfect reviewers’
inter-rater agreement [26].
From a total of 12 studies, 10 were observational studies (6 cross-sectional [30–35] and
four case-control [36–39]), 1 was an animal study [40], and 1 was an in vitro study [41].
Different fluids/tissues were used for the HDPs’ analysis, including GCF [30,31,34,36–38],
saliva [33,35,39], GT [32], and human oral epithelial cells [41]. However, one study [40] used
both blood and GT for the analysis. Three studies investigated adrenomedullin [30,36,38],
two studies investigated HBD 1 [33,34], and study each investigated hBD 1 and hBD 3 [31],
hBD 2, hBD 3 and hCAP18/LL-37 [32], hBD 2 [35], hCAP18/LL-37 [37], hBD 1, hBD 2, hBD
3 and hCAP18/LL-37 [39], and hBD 3 [40] and lipocalin 2 [41].
For the human-based studies, the total number of patients was 1011. However, for the
one animal study [40], total of eight monkeys were utilized. From the 12 studies, 9 showed
greater levels of HDP in the DM2 group with PD [30–33,35,36,38,40,41]. In one study, the
healthy control group showed more increased levels of HDP than the DM2 group with
PD [34,37]. Interestingly, one study showed greater levels of hCAP18/LL-37 and decreased
hBD 1, hBD 2, and hBD 3 levels in DM2 with the PD group than the CP group [39].
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Table 1. Characteristics of studies demonstrating association between HDP, PD, and DM2.
Author/Year

Analysed Fluid/Tissue

Outcomes

HDP Levels (Increase
or Decrease)

Patients with DM2 + CP: 45
Patients with CP with no DM2: 30
Periodontally and systemically healthy
patients (control): 15

(1) DM2 + CP group > other groups (p < 0.001)
(2) CP group > healthy controls (p < 0.001)

Increase

Patients with DM2 and gingivitis: 20
Patients with DM2 and CP: 20
HG patients: 20
HCP patients: 20

For both hBD 1 and 3:
(1) DM2 and CP group > other groups
(p < 0.05)
(2) DM2 and gingivitis group > HG group
(p < 0.05)
(3) DM2 and gingivitis group > HCP group
(p < 0.05)
(4) HCP group > HG group (p <0.05)

Increase

Patients with DM2 + GP: 14
Healthy patient with GP: 11
Healthy patients (control): 13

(1) DM2 + GP group > healthy controls
(hCAP18/LL-37: p = 0.002; hBD 2: p = 0.005;
hBD 3: p = 0.007);
(2) Insignificant difference between GP group
and DM2 + GP group (p > 0.05);
(3) Insignificant difference between healthy
controls and GP group (p > 0.05)

Increase

hBD 1

Patients with DM2 + CP: 116
Patients with CP with no DM2: 95
Periodontally and systemically healthy
patients: 69

(1) DM2 + CP > healthy controls (p < 0.05)
(2) CP > healthy controls (p < 0.05)

Increase

Healthy controls > other groups (p < 0.05)

Decrease

DM2 + GP > CP group (p < 0.05)

Increase

Investigated HDP

Study Participants

Cross-sectional studies

Suchetha et al. (2013) [30]

Ertugrul et al. (2013b) [31]

GCF

GCF

Yilmaz et al. (2015) [32]

GT

Soraia Aguiar de Melo Dias
et al. (2018) [33]

Saliva

Adrenomedullin

hBD 1
hBD 3

hCAP18/LL-37
hBD 2
hBD 3

Yilmaz et al. (2018) [34]

GCF

hBD 1

Patients with DM2 + GP: 21
Systemically healthy patient with GP: 18
Periodontally healthy patients with DM2: 18
Periodontally and systemically healthy
patients (control): 24

Alex et al. (2019) [35]

Saliva

hBD 2

Patients with DM2 + GP: 20
Systemically healthy patient with CP: 20
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Table 1. Cont.
Author/Year

Outcomes

HDP Levels (Increase
or Decrease)

Adrenomedullin

Patients with DM2 + CP: 21
Healthy patients with DM2: 21
Patients with CP with no DM2: 21
Periodontally and systemically healthy patients
(control): 21

(1) DM2 + CP group > CP group, DM2 group
and healthy controls
(p < 0.05)
(2) DM2 group > CP group and healthy controls
(p < 0.05)
(3) CP group > healthy controls (p < 0.05)

Increase

hCAP18/LL-37

Patients with DM2 + CP: 5
Periodontally health patients with DM2: 5
Patients with CP with no DM2: 5
Periodontally and systemically healthy patients
(control): 5

(1) DM2 + CP < healthy controls (p < 0.05)
(2) CP < healthy controls (p < 0.05)

Decrease

GCF

Adrenomedullin

Patients with DM2 + CP: 30
Periodontally health patients with DM2: 30
Patients with CP with no DM2: 30
Periodontally and systemically healthy patients
(control): 30

(1) DM2 + CP > other groups (p < 0.05)
(2) DM2 group > healthy controls (p < 0.05)
(3) CP group > healthy controls (p < 0.05)

Increase

Saliva

hCAP18/LL-37
hBD 1
hBD 2
hBD 3

Patients with DM2 + CP: 63
Periodontally health patients with DM2: 58
Patients with CP with no DM2: 29
Periodontally and systemically healthy patients
(control): 28

(1) DM2 + CP group > healthy controls
(hCAP18/LL-37: p < 0.05)
(2) CP group > other groups (hBD 1: p < 0.05;
hBD 2: p < 0.05; hBD 3: p < 0.05)

Increase for hCAP18/LL-37
Decrease for hBD 1, 2 and 3

DM2 + PD > control group (p < 0.05)
Serum blood level of hBD 3 and gingival
expression of hBD 3 mRNA in DM monkeys
were considerably higher than in the healthy
controls.

Increase

AGEs increased the expression levels of
lipocalin 2 in HOEC

Increase

Analysed
Fluid/Tissue

Investigated HDP

Study Participants
Case-control studies

Ertugrul et al. (2013a) [36]

Marinho et al. (2019) [37]

Pragada et al. (2019) [38]

Yilmaz et al. (2020) [39]

GCF

GCF

Animal study

Jiang et al. (2018) [40]

Blood
GT

hBD 3

Monkeys with DM2 + PD: 5
Periodontally and systematically healthy
monkeys (control): 3
In vitro study

Kido et al. (2020) [41]

HOEC

Lipocalin 2

-

Advanced glycation end products (AGEs); Cathelicidin (hCAP18/LL-37); Chronic periodontitis (CP); Diabetes mellitus type 2 (DM2); Healthy patients with gingivitis (HG); Healthy patients with chronic
periodontitis (HCP); Human β-defensin (hBD); Human oral epithelial cells (HOEC); Generalised periodontitis (GP); Gingival crevicular fluid (GCF); GT (Gingival tissue); Periodontal disease (PD).
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3.2. Quality Appraisal
All the studies [36–39] evaluated by NOS for cross-sectional studies scored more
than 7, suggesting high quality of the studies (Figure 2). For studies assessed by the
NOS modified for cross-sectional studies, 1 study [30] scored 9 points (very good study),
4 studies [31–34] scored 8 points (good studies), and 1 study [35] scored 6 points (satisfactory study) (Figure 3). The only animal study [40] was categorised to have unclear bias
risk, as assessed by the SYRCLE tool (Figure 4).

Figure 2. Quality appraisal of case-control studies via Newcastle Ottawa scale. A study can be awarded a maximum of one
star (*) for each numbered item within the Selection and Exposure categories. A maximum of two stars can be given for
Comparability.

Figure 3. Quality appraisal of cross-sectional studies via modified Newcastle Ottawa scale. A study can be awarded a
maximum of one star (*) for each numbered item within the Comparability categories. A maximum of five stars can be given
for the Selection category (two stars for the Ascertainment of the exposure) and three stars can be given for the Outcome
category (two stars for the Assessment of outcome).
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Figure 4. Quality appraisal of animal study via SYRCLE tool.

4. Discussion
Diabetes mellitus is a group of metabolic disorders characterised by chronic hyperglycaemia, causing dysfunction in carbohydrate, protein and fat metabolism due to a complete
lack of insulin or its effect [42]. Diabetes Mellitus type 1 (DM1) is insulin-dependent and is
supposed to be an autoimmune disorder. On the other hand, DM2 is not insulin-dependent
and has chronic inflammatory process as a main component of its pathophysiology [43].
Because chronic periodontitis (CP) is also a chronic inflammation, the link between PD
and DM2 is much greater than the link between PD and type 1 DM [31]. It is widely
acknowledged that there is a bi-directional relationship between PD and DM2, and that
DM2 frequently aggravates the devastating process of PD, and vice versa [44].
Several studies explored the biological correlation between DM2 and PD. In certain
investigations, DM2 has been linked to a decrease in tissue HDP synthesis [45,46], although
one study reported an insignificant difference in serum HDP levels [47]. PD and DM2 both
are complicated disorders comprising a genetical constituent. Decreased hBDs and greater
hADs levels have been observed in DM2, related to genetics; correspondingly, lower hBD 2
has been observed in severe CP in regard to genetical copy number diversity [48,49]. Furthermore, the function of defensins in mediating tissue destruction in DM2 complications
has been discussed [48]. These findings potentially point to shared genetic susceptibility
factors underpinning poor regulation and function of HDP in DM2 as well as PD. Aside
from genetical susceptibility, hyperglycaemia and PD may alter HDP expression as well as
function in epithelial cells independently [45]. The chemicals dicarbonyls methylglyoxal
and glyoxal are generated in response to hyperglycaemia and have been shown to degrade hBD 2; the suppression in immunity emphasises the enhanced sensitivity to cellular
invasion by Gram-negative bacteria observed in DM2 [50].
Several human investigations were conducted to determine the involvement of HDPs
in people with PD and DM2 (Table 1). Despite the fact that this research involved distinctive
types of samples (GCF and GTs) and targeted several different HDPs, they all yielded
comparable results, suggesting upregulation of HDP in DM2 with periodontitis, with the
exception of three studies that revealed downregulation of hCAP18/LL-37 [37], hBD 1 [34]
and hBD 1, hBD 2, and hBD 3 [39]. The hBD 1 levels in GCF were considerably greater
in patients with DM2 and CP than in systemically healthy patients with CP alone [31]. In
contrast, a comparable study that looked at hBD 2 levels in GT [32] did not find significant
differences between the two groups. The hBD 3 expression in GCF [31] and GT [32,40] have
revealed similar outcomes, signifying that DM2 may upregulate hBD 3 levels in individuals
with PD. Likewise, hCAP18/LL-37 [32,39], lipocalin 2 [41], and adrenomedullin [30,36,38],
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a multifunctional vasopeptide, have been overexpressed in individuals with DM2 with
PD. However, a paucity of experimental substantiation of the DM effects on the molecular
mechanisms behind expression of HDP in GT still exist.
The animal study [40] investigating the expression of hBD 3 in GT showed upregulation in DM2 rhesus monkeys compared to the control group. The result of this animal
study was consistent with research by Yilmaz et al. (2015) [32] that was conducted on
humans and also demonstrated overexpression of hBD 3 in GT.
Likewise, an in vitro study [41] showed that the expression of lipocalin 2 in human
oral epithelial cells was increased due to advanced glycation end products (AGEs), which
is a major factor that causes DM2 complications and induces inflammatory responses in
some systemic tissues.
A potential explanation of the HDPs’ upregulation in DM with PD is the accumulation
of AGEs forming due to chronically elevated blood levels of glucose, and enhanced AGE
serum levels resulting in simultaneous secretion into the GCF [51]. Increased AGE levels
not only cause thickening in periodontal tissue basal membrane and vascular injury,
but they also harm endothelial cells, polymorphonuclear neutrophils, monocytes, and
macrophages [52]. The resulting loss of vascular structure and cell dysfunction impedes
chemotactic factor migration and activity, reducing leukocytes’ ability to protect periodontal
tissues from the pathogens’ effect [31,36]. This results in an elevated periodontal pathogen
load, leading to an augmented gingival HDP release to fight infection and halt the loss
of periodontal tissue. Nevertheless, such putative protective functions of elevated HDPs
remain insufficient to restrict inflammation of periodontal tissues and promote appropriate
wound healing [31,32,36].
Three investigations, on the other hand, found HDP downregulation in DM2 with CP.
This could be explained by the fact that hyperglycaemic circumstances inhibit expression
of hBD 3 at the mRNA as well as protein levels in human keratinocytes [45]. Excess
AGE production inhibited P38 mitogen-activated protein kinases’ (p38MAPK) signalling,
which explained their findings. Another in vitro investigation found that while ageing can
cause a transitory rise in p38MAPK signalling, at greater levels ageing causes HDPs to
be less expressed [53]. Other research, however, has found elevated amounts of hBDs in
DM2 [31–33,35,40]. These changes may be due to different sources of sampling such as
gingiva, GCF, saliva, and participant DM2 management.
Although these few studies attempted to identify the possible relationships among
HDPs, PD, and DM2, the fundamental variables and mechanisms remain unknown. Some
questions about this matter are yet unanswered: How can DM2 and PD processes participate in HDP production disruption? What role do HDPs play in poor glycaemic control
and consequent PD? Furthermore, the effects direction of HDP levels on severity of DM2
and PD remains unknown. More follow-up studies with a bigger sample size are necessary
to verify HDPs as a biomarker in PD and DM2 advancement, as well as to explain the
vagueness of its involvement. In addition, future research should include in vitro studies in
human gingival epithelial cells/keratinocytes investigating the mechanism of DM2 on HDP
expression. Furthermore, randomised controlled clinical trials of periodontal treatment
should be conducted comparing DM2 and CP with a CP-only group and healthy patients
to explore the consequence of periodontal therapy on HDP levels in these individuals.
Few limitations were encountered in this review. First, no meta-analysis could have
been conducted as a result heterogenous data such as study designs, population assessed,
tissue type analysed, and finally the HDP investigated in the study. Secondly, only one
in vitro and one animal study were retrieved after thorough search, showing the scarcity of
exploration of HDPs in DM2 and PD in these study designs. Thirdly, the one animal study
included was classified to be of unclear risk on the SYRCLE tool. Fourthly, the quality
appraisal of the one in vitro study could not be performed as there is no validated tool
available. Lastly, a majority of studies included in this review were the cross-sectional
and case-control design, and that did not allow us to monitor possible fluctuations in the
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secretions of HDPs in response to changes in the glycaemic status, which can be considered
as a limitation.
5. Conclusions
A hyperglycaemic environment may result in periodontal tissue destruction by accelerating inflammatory response and weakening the defence system in periodontal tissue.
According to the current literature, HDPs have a potential mechanistic linkage between PD
and DM2. Those data, however, are relatively restricted, and more human, animal, and
laboratory investigations are required to elucidate the authenticity of these connections.
A better understanding of HDPs as a conjoint mediator is critical for determining their
relevance for treatment or diagnostic possibilities, given the two-way association between
PD and DM2.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/diagnostics11122210/s1, Table S1: Search tracking.
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